Pascal Biosciences Inc
XTSX:PAS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pascal Biosciences Inc
Interest Income Expense
Pascal Biosciences Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pascal Biosciences Inc
XTSX:PAS
|
Interest Income Expense
-CA$24.3k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Interest Income Expense
CA$1.7m
|
CAGR 3-Years
451%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Interest Income Expense
$9.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
44%
|
CAGR 10-Years
6%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Interest Income Expense
$28.2m
|
CAGR 3-Years
93%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Interest Income Expense
-CA$150k
|
CAGR 3-Years
39%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Interest Income Expense
$6.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pascal Biosciences Inc
Glance View
Pascal Biosciences, Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2012-03-16. The firm is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The firm operates in the segment of biotechnology research and development. The firm is focused on developing cannabinoid-based and targeted therapeutics to fight cancer. Its cannabinoid portfolio includes PAS-403, PAS-393 and Cannabinoid for corona virus disease-2019 (COVID-19). Its PAS-403 is a small molecule therapeutics for the treatment of glioblastoma. Its PAS-393, is an immune-stimulatory cannabinoid used in combination with checkpoint inhibitor therapy to treat multiple cancers. In addition, it is developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas.
See Also
What is Pascal Biosciences Inc's Interest Income Expense?
Interest Income Expense
-24.3k
CAD
Based on the financial report for Nov 30, 2022, Pascal Biosciences Inc's Interest Income Expense amounts to -24.3k CAD.
What is Pascal Biosciences Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 1Y
-966%
Over the last year, the Interest Income Expense growth was -966%.
